Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.
A personalized mRNA vaccine for melanoma has proven effective in reducing the risk of cancer recurrence, according to phase III clinical trial results announced by the trial's sponsors. This marks the first successful application of mRNA technology in a late-stage cancer treatment. The vaccine utilizes the same mRNA technology that underpins COVID-19 vaccinations.
While potential prices may be influenced by local taxes determined during the purchasing process, the vaccine's efficacy in melanoma presents promising prospects for personalized medicine.
Written by urgent.news from Nature's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
